RT Journal Article
SR Electronic
T1 Asymptomatic infection and herd immunity of COVID-19 in Wuhan and Japan
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.05.01.20087155
DO 10.1101/2020.05.01.20087155
A1 Junko Kurita
A1 Tamie Sugawara
A1 Yasushi Ohkusa
YR 2020
UL http://medrxiv.org/content/early/2020/05/06/2020.05.01.20087155.abstract
AB Background The COVID-19 outbreak has shown two inconsistent phenomena: its reproduction number is almost two; and it shows earlier and lower peaks for new cases and the total number of patients.Object To resolve this inconsistency, we constructed a mathematical model to explain these phenomena.Method To outbreak data from Wuhan, China and Japan, we applied a susceptible–infected–recovery model with the proportion of asymptomatic patients among infected people (q) as a key parameter for estimation, along with the basic reproduction number (R0).Results The first outbreak peak was recorded in Japan on April 3 for those infected on March 29. Their R0 and q were estimated respectively as 3.19 and 99.32% in Wuhan. In Japan, these were estimated around the peak as 2.96 and 99.99%.Discussion and Conclusion By introducing a very high proportion of asymptomatic cases, the two inconsistent phenomena might be resolved. Especially in Japan, the asymptomatic cases were 60 times higher than those of China.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe author(s) received no specific funding for this work.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesJapan Ministry of Health, Labour and Welfare. Press Releases. (in Japanese) https://www.mhlw.go.jp/stf/newpage_10723.html